CJC-1295 (No DAC) + Ipamorelin 10mg: A Technical Overview

Reviewed for accuracy by the Gorilla Research Labs research team · 2026-07-04

Peptide Research Reference CJC-1295 (No DAC) + Ipamorelin 10mg: A Technical Overview This document outlines the biochemical properties and laboratory research applications of the synthetic peptide combination comprising CJC-1295 (without Drug Affinity Complex) and Ipamorelin.

1. Overview & Classification

CJC-1295 (No DAC) and Ipamorelin are synthetic peptide analogs categorized within the field of endocrine research. CJC-1295 (No DAC) is a modified peptide analog of growth hormone-releasing hormone (GHRH), while Ipamorelin is classified as a selective growth hormone secretagogue (GHS) acting as a ghrelin receptor agonist. In laboratory settings, these compounds are frequently utilized in tandem to investigate complex signaling pathways involving pituitary regulation. Because these molecules are synthetic, their specific molecular weights and chemical identifiers are subject to batch-specific synthesis and should be verified against the provided Certificate of Analysis (COA) or the PubChem database.

2. Molecular Target & Mechanism

The research utility of this combination lies in the distinct pathways targeted by each constituent. CJC-1295 (No DAC) functions as a GHRH analog, binding to the GHRH receptor (GHRHR) located on the somatotroph cells of the anterior pituitary gland. By interacting with this G-protein coupled receptor, it is reported in laboratory studies to modulate the cAMP signaling pathway. Ipamorelin acts as a selective agonist at the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a). Unlike non-selective secretagogues, Ipamorelin is noted in literature for its high affinity for the GHS-R1a while demonstrating limited interaction with other hormone receptors. The simultaneous presence of these two compounds in a research model is studied for their potential to probe the synergistic interactions between the GHRH and GHS-R1a signaling axes. • GHRHR: Primary target of CJC-1295 (No DAC). • GHS-R1a: Primary target of Ipamorelin. • Signaling Modulation: Investigation of cAMP and calcium-dependent pathways.

3. Why Researchers Use It

Researchers utilize this peptide combination as a tool to explore the dynamics of pituitary hormone regulation in vitro and in controlled research models. By applying these ligands, investigators can observe how the GHRH and GHS-R1a pathways influence cellular activity within the somatotropic axis. The use of the "No DAC" variant of CJC-1295 is particularly significant in experimental design where a shorter half-life is preferred to allow for more precise control over the timing of receptor stimulation. This allows researchers to perform time-resolved studies on receptor desensitization and intracellular signaling cascades without the extended pharmacological activity associated with DAC-modified peptides.

4. Research Context

The investigation of GHRH and GHS-R1a analogs is central to endocrine research. Laboratory studies characterize these pathways to better understand the regulatory mechanisms governing the secretion of pituitary hormones. By utilizing these ligands, researchers can map the feedback loops and signal transduction events that occur at the cellular level. Current research efforts often focus on the interaction between these receptors and the downstream enzymatic activity they trigger. These studies are essential for elucidating the complex interplay between hypothalamic and pituitary signaling molecules, providing insight into the fundamental biology of peptide-receptor affinity and signal amplification.

5. Handling, Stability & Storage for Laboratory Use

For in-vitro research, peptides must be handled under sterile laboratory conditions to maintain chemical integrity. Lyophilized peptides should be stored at -20°C or -80°C for long-term stability. When preparing stock solutions, researchers typically use a solvent appropriate for the specific peptide's solubility profile, such as deionized water or a dilute acetic acid solution, followed by sterile filtration. Repeated freeze-thaw cycles should be avoided to prevent degradation of the peptide structure. Once reconstituted, stock solutions should be aliquoted and maintained at low temperatures. All handling should occur within a controlled environment to prevent contamination and ensure the accuracy of subsequent assays.

6. Purity & Analytical Verification

The validity of research findings is dependent upon the purity and structural integrity of the compounds used. Analytical verification is typically conducted via High-Performance Liquid Chromatography (HPLC) to determine chemical purity and Mass Spectrometry (MS) to confirm molecular identity. Researchers should consult the specific Certificate of Analysis (COA) provided with each batch. A COA details the results of these analytical tests, ensuring that the compound meets the required specifications for laboratory experimentation. Reliance on unverified materials can introduce variables that compromise the reproducibility of in-vitro models.

7. How It Relates to Other Compounds in Its Research Class

CJC-1295 (No DAC) and Ipamorelin belong to the broader class of growth hormone-related peptides. Other compounds in this category include hexarelin, GHRP-2, and GHRP-6, which also target the GHS-R1a. However, Ipamorelin is often distinguished in research for its reported selectivity profile compared to earlier-generation secretagogues. CJC-1295 (No DAC) is compared to endogenous GHRH and other modified analogs, such as Sermorelin. The primary distinction in research models is the modification of the peptide sequence, which affects the peptide's susceptibility to enzymatic degradation and its affinity for the GHRH receptor. These differences allow researchers to select specific tools based on the required duration of receptor activation.

8. Frequently Asked Research Questions

What is the primary difference between CJC-1295 with DAC and without DAC? The "DAC" refers to the Drug Affinity Complex, which allows the peptide to bind to serum albumin. The "No DAC" variant lacks this modification, resulting in a shorter half-life and a different pharmacokinetic profile in research models, which is often preferred for short-term in-vitro assays. Why is Ipamorelin considered a selective agonist? In laboratory studies, Ipamorelin has been shown to exhibit high specificity for the GHS-R1a receptor with minimal affinity for other receptors, reducing the likelihood of off-target activity in experimental models. How is peptide stability verified in the laboratory? Stability is verified through periodic HPLC analysis to monitor for degradation products or changes in the impurity profile over time under varying storage conditions. Are these peptides suitable for in-vivo research? These compounds are synthesized for laboratory research applications. Any application in an in-vivo model must adhere to the institutional guidelines and ethical protocols governing animal research. Research use only — no structure/function or human-use claims are made. This information is provided for educational purposes regarding the chemical and biochemical properties of the substances described.